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Abstract. Epithelial protein lost in neoplasm-α (EPLIN-α) is 
a cytoskeletal protein whose expression is often lost or is aber-
rant in cancerous cells and tissues and whose loss is believed 
to be involved in aggressive phenotypes. This study examined 
this molecule in human epithelial ovarian tissues and investi-
gated the cellular impact of EPLIN-α on ovarian cancer cells 
(EOC), SKOV3 and COV504. The expression of EPLIN-α 
in human ovarian tissues and EOC was assessed at both the 
mRNA and protein levels using reverse transcription-PCR 
(RT-PCR) and immunohistochemistry, respectively. In vitro 
assays for cellular matrix adhesion and migration (confirmed 
by an electrical cell substrate impedance sensing (ECIS) based 
method), invasion and cell growth were employed in order 
to assess the biological influence of EPLIN-α expression on 
EOC cells. Immunohistochemical analysis of ovarian cancer 
samples demonstrated that only a small number expressed 
EPLIN-α protein. Downregulation of EPLIN-α protein in 
EOC cell lines increased the growth, invasion, adhesion and 
migration in vitro. This EPLIN-α downregulation may have 
a prognostic value. From these data, we conclude that down-
regulation of EPLIN-α may be associated with poorer patient 
prognosis, and that this molecule appears to play a tumour 
suppressor role by inhibition of EOC growth and migration.
Introduction
Epithelial ovarian cancer (EOC) has the highest mortality rate 
among all gynaecological malignancies, metastasis is the main 
cause of death in patients with EOC. Epithelial protein lost 
in neoplasm (EPLIN), first discovered through its differential 
expression between normal oral epithelial cells and human 
papilloma virus (HPV)-immortalised oral epithelial cell 
lines (1), is a regulator of cytoskeletal dynamics. It has been 
shown to influence actin stabilization, to regulate actin turn-
over and to link the cadherin-catenin complex to F-actin (2-4). 
EPLIN exists as two isoforms (EPLIN-α, EPLIN-β) which 
arise due to transcription from two distinct promoter regions 
(5,6). EPLIN-α appears to play key roles in regulating actin 
dynamics and motility in normal cells. Cytoplasmic expression 
of EPLIN-α has been detected in a fibrillar pattern, similar to 
that of actin fibres (5). Research conducted in our laboratory 
has previously revealed that EPLIN-α expression was dys-
regulated in clinical prostate and breast cancer samples and 
lower EPLIN-α levels were associated with more aggressive 
cancer and poor survival, and that EPLIN-α may impact on 
the angiogenic process (7,8). It has also been suggested that the 
loss of EPLIN-α expression in cancerous cells may contribute 
to genomic instability and to the enhanced motility and inva-
siveness of cancer cells (2-4,7-10). All these findings indicate 
that EPLIN-α may act as a tumour suppressor. Recent research 
has shown that the special AT-rich-binding protein 2 (SATB2) 
plays a role as a novel regulator of osteosarcoma invasion, in 
part via effects on EPLIN and the cytoskeleton (11). Such find-
ings provide conclusive evidence that reduction of EPLIN has 
the potential to disrupt cell-cell adhesion via disorganization 
of the adherens junctions, which promotes IGF1R signalling. 
This is followed by the attenuation of E-cadherin expression 
and the formation of an EMT-like phenotype (12). Whilst the 
importance and role of EPLIN-α in a number of cancers is 
beginning to become apparent, its role in EOC is currently 
unknown.
In this study, we investigated the clinical and biological 
role of EPLIN-α in human ovarian cancer. This study provides 
evidence that EPLIN-α knockdown in ovarian cancer cells can 
increase the aggressive nature of these cells.
Materials and methods
Clinical sample collection, processing and IHC staining. 
All clinical samples examined in this study were obtained 
from surgically removed ovarian tissues of inpatients in 
Wuhan Tongji Hospital of Huazhong University of Science 
and Technology (Wuhan, China) from 2013 to 2014; patients 
who had received pre-operative radiotherapy or chemotherapy 
were excluded. Immunohistochemistry was performed on 
30 epithelial ovarian serous carcinomas, 15 samples were 
non-metastatic and 15 had lymph node or omentum metastases. 
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All of the tumour samples were obtained from the primary 
tumour site. Diagnosis was confirmed by histopathology in all 
cases. All protocols were reviewed and approved by the ethics 
committee of Wuhan Tongji Hospital, and all the patients gave 
their written informed consent.
Tissue sections (4 µm) were prepared from formalin-fixed 
paraffin embedded blocks. IHC was performed using rabbit 
anti-EPLIN-α antibody (Calbiochem, Nottingham, UK) and 
the Vectastain® Elite Universal ABC kit (Vector Laboratories, 
Peterborough, UK). The de-paraffinized sections were 
rehydrated in Tris-buffered saline (TBS). Antigen retrieval 
was then performed by heating the samples for 20 min in a 
microwave in 1 mM EDTA buffer (pH 8.0). The sections were 
cooled and washed in tap water (10 min). Non-specific binding 
was blocked with 5-10% goat serum (90 min) and slides were 
then incubated with the primary EPLIN-α antibody (1:100 in 
TBS) for 1 h. Following sequential 30-min incubations with 
mouse biotinylated secondary and ABC complex, respec-
tively, the target protein was visualised using freshly prepared 
3,3-diaminobenzidine (DAB) (Sigma-Aldrich, Poole, UK). 
Slides were rinsed with water, counterstained with haema-
toxylin, dehydrated, cleared in xylene and mounted in DPX. 
Negative controls were prepared by substituting the primary 
antibody with TBS. The sections were then viewed under the 
Leica MC120 microscope, photographed and the intensity and 
localisation of the staining was analysed.
Cell lines and culture conditions. Human ovarian epithelial-
serous carcinoma cell lines SKOV3 and COV504 (ECACC, 
European Collection of Animal Cell Culture, Salisbury, UK) 
were routinely maintained in DMEM-F12 medium supple-
mented with 10% fetal bovine serum, penicillin (100 U/ml), 
streptomycin (100 µg/ml) and amphotericin B (0.25 µg/ml) 
(Sigma). Cells were incubated at 37˚C with 95% humidity in 
5% CO2.
Generation of EPLIN-α ribozyme transgenes. Anti-Eplin-α 
hammerhead ribozyme transgenes were synthesised and cloned 
into pEF6/V5-His-TOPO plasmid vector as described in previous 
studies (13-15). Purified EPLIN-α plasmids (8 µg) and control 
plasmid vectors were then transfected into SKOV3 and COV504 
cells (300 V, 1500 µF), (1x106/ml) using a Gene Pulser X cell 
electroporator (Bio-Rad Laboratories, Hemel Hempstead, UK). 
Transfected cells underwent selection for ~2 weeks with blasti-
cidin (5 µg/ml) (Melford Laboratories, Ipswich, UK). Positively 
transfected cell cultures were maintained in medium containing 
0.5 µg/ml blasticidin. The transfectants were verified for their 
expression of Eplin-α mRNA and protein, and the successful 
clones were used in subsequent studies.
RNA extraction and reverse transcription PCR. Total cellular 
RNA was isolated from the EOC cells using Tri-reagent 
according to the manufacturer's  instructions (Sigma-Aldrich). 
RNA concentration and quality were determined through 
spectrophotometric measurement (NanoPhotometer, Implen, 
Mϋnich, Germany). RNA (500 ng) was reverse transcribed 
into cDNA using an Applied Biosystems high capacity reverse 
transcription kit (Life Technologies, Paisley, UK). DNA 
quality was verified using GAPDH PCR (sense, GGCTGCTTT 
TAACTCTGGTA; antisense, GACTGTGGTCATGAGTC 
CTT) which was also used as a loading control. Eplin-α 
mRNA levels were assessed using primers (sense, AAGCA 
AAAATGAAAACTAAG; anti sense, GACACCCACCTTAG 
CAATAG). PCR was carried out in an Applied Biosystems 
thermocycler using a Go Taq green PCR reaction mix (Promega 
UK, Southampton, UK). Cycling conditions were 94˚C for 
5 min, followed by 28 cycles of 94˚C for 30 sec, 55˚C for 30 sec 
and 72˚C for 30 sec. This was followed by a final 7-min extension 
period at 72˚C. The products were visualized on 2% agarose 
gel stained with SYBRSafe (Life Technologies).
Immunofluorescence staining. Cells were seeded at a density 
of 20,000 cells per well in an 8-well chamber slide (Merck-
Millipore, UK). Following an overnight incubation, the 
medium was aspirated and the cells were fixed in 4% formalin 
(4˚C, 20 min). Following fixation, the cells were rehydrated in 
phosphate-buffered saline (PBS) for 20 min at room tempera-
ture before being permeabilised for 5 min in a 0.1% Triton 
in PBS. Non-specific binding was blocked by 1-h incubation 
in phosphate-buffered saline (PBS) containing 5-10% goat 
serum. Cells were incubated for 1 h with Eplin-α antibody 
(1:100) in PBS blocking solution (Calbiochem). Slides were 
washed 3x5 min in PBS then incubated on a shaker plat-
form in the dark for 1 h with FITC conjugated anti-mouse 
secondary antibody (Insight Biotechnology Ltd., Middlesex, 
UK) and 1:1,000 DAPI (Roche, Hertfordshire, UK). Slides 
were finally washed 3x5 min PBS, mounted with Fluorsave 
(Merk-Millipore, UK) and visualised using an EVOS fluores-
cence auto imaging system (Life Technologies).
Western blot analysis. Cell lines were grown to 70% confluence, 
monolayers were washed with PBS and lysed in ice cold lysis 
buffer (50 mm Tris, 150 mM NaCl, 5 mM EGTA, 1% Triton 
X-100 pH 7.5) supplemented with protease inhibitor cocktail 
(Roche). Lysates were clarified by centrifugation (12,000 rpm, 
15 min, 4˚C) and the protein concentrations in the supernatants 
were determined using the DC Protein Assay kit (Bio-Rad, 
Hemel Hempstead, UK). Protein was reduced and denatured by 
boiling (5 min) in Laemmli buffer (Sigma-Aldrich) and 20 µg 
protein samples were resolved by SDS-PAGE and transferred 
onto nitrocellulose membrane (GE Healthcare Life Sciences, 
Buckinghamshire, UK). After blocking for 1 h in 5% skimmed 
milk (TBS/Tween: 140 mM NaCl; 50 mM Tris, 0.05% Tween 
pH 7.4), blots were incubated overnight at 4˚C with primary 
antibodies Eplin-α (1:500 prepared in TBS/Tween/1% milk) 
and GAPDH (1:1,000 in TBS/Tween/1% milk) (Santa Cruz 
Biotechnology, Heidelberg, Germany) was used as a loading 
control. Blots were washed with TBS/Tween and bound anti-
bodies were detected after 1-h incubation (room temperature) 
with appropriate horseradish peroxidase-conjugated secondary 
antibody (1:1,000, Sigma-Aldrich). Following 3x5 min TBS/
Tween washes, protein bands were visualized using enhanced 
chemiluminescence (Luminata Forte, Millipore, Herefordshire, 
UK), and photographed using a UVITech imager (UVITech, 
Inc., Cambridge, UK).
Cell proliferation assay. Cells were seeded into 96-well plates 
at a seeding density of 3,000 cells per well with 12 replicates/
experiment. Cells were fixed with 4% formalin after 1, 3 and 
5 days growth. Fixed cells were stained with 0.5% crystal violet, 
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washed and dried. Dye was re-solubilised in 200 µl acetic 
acid/well and absorbance was determined at 540 nm using an 
ELx800 multi-plate reader (BioTek UK, Bedfordshire, UK). 
Each experiment was repeated at least 3 times. For each cell 
line, analysis compared cell number (absorbance) on days 3 
and 5 relative to day 1.
Cell adhesion assay. Cell-matrix adhesion was examined 
using an in vitro Matrigel adhesion assay adapted from a 
previously described method (16-18). Cells were seeded into 
96-well plates pre-coated with 5 µg/well Matrigel basement 
membrane matrix (BD Biosciences, Oxford, UK). After 
40 min of incubation (37˚C) the cells were washed with PBS 
to remove unbound cells. The remaining adherent cells were 
fixed with 4% formalin, stained with 0.5% crystal violet, 
visualized under a microscope (x20) and cell number counted 
per field of view. Four counts were made from each 6 replicate 
wells and results were expressed as mean cell number/well. 
Each experiment was repeated 3 times.
Cell invasion assay. Cell invasive capability was examined 
using an in vitro Matrigel invasion assay. Transwell inserts 
(Greiner Bio-One, Stonehouse, UK) with 8.0-µm pore size 
were coated with 50 µg Matrigel (BD Biosciences), dried at 
55˚C and rehydrated with 100 µl serum-free medium before 
seeding 4,000 cells per insert. After 48 h of incubation at 37˚C, 
non-invasive cells and Matrigel were removed from the inside 
of the inserts with a cotton swab. Cells that had invaded to the 
underside of the insert were fixed (4% formalin), stained with 
0.5% crystal violet and washed. Cell invasion was quantitated 
by counting the cell number in 4 fields of view (x20 magni-
fication). Data were analysed as mean cell number per field 
of view for 3 independent experiments with 3 replicates per 
experiment. Results were confirmed by incubating the stained 
inserts in 10% acetic acid. Absorbance of solubilized crystal 
violet was determined at 540 nm.
Migration assay. A cellular wounding assay was used to study 
directional cell migration in vitro as previously described (19). 
In brief, cells were cultured to confluence in a 24-well plate 
before scratching the cell monolayer with a 10-µl pipette tip. 
The closure of the induced wound, through the migration of 
cells, was tracked and recorded over a 36-h period using an 
automated cell imaging system EVOS (Life Technologies). 
Using ImageJ software, the relative distance cells migrated 
was calculated using multiple measurements of the width of 
wound gap after 12, 24 and 36 h compared to 0 h.
Electric cell-substrate impedance sensing (ECIS)-based 
attachment and migration assay. Cell attachment and migra-
tion were further studied using an ECIS Z-Theta instrument 
and 96W1E arrays (Applied Biophysics, Inc., NY, USA) as 
previously described (7). Briefly, 40,000 cells per well were 
added to the ECIS arrays. Impedance and resistance of the cell 
layer was immediately recorded for a period of ≤5 h. When 
confluence was reached, the monolayer in each well was elec-
trically wounded at 2,600 µA and 6,0000 Hz for 20 sec to 
create a 250-µm wound per well. Impedance and resistance 
Figure 1. Expression of EPLIN-α in ovarian cancer. Immunohistochemical staining of EPLIN-α in human ovarian tissues (A). Basal expression of EPLIN-α 
mRNA examined in ovarian cancer cell lines using RT-PCR (B). High expression of EPLIN-α (160 bp) in SKOV3 and COV504 cells (28 cycles). GAPDH 
(475 bp) was used as an equal loading control. The negative control was sterile water and the positive control CDNA from the normal prostate cell line PZHPV7.
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of the wounded cells as they migrated in the wound was then 
recorded for a period of up to 10 h. Data were analysed using 
the ECIS software, supplied by the manufacturer.
Statistical analysis. All statistical analysis was performed 
using the paired t-test for normally distributed data (data 
were tested for normal distribution before further statistical 
analyses were carried out). Differences were considered to be 
statistically significant at p<0.05.
Results
Expression of Eplin-α in human ovarian tissues and EOC cells. 
IHC staining of 15 sections of non-metastastic and 15 sections 
of metastatic epithelial cancerous ovarian growths was used to 
assess Eplin-α expression pattern in the clinical setting. Eplin-α 
expression was detected in 6/30 tissue samples examined; 2/15 
non-metastatic tumours and 4/15 metastatic tumours were local-
ised in epithelial cell cytoplasm. Where staining was observed 
there was no difference in the intensity of the stain between non-
metastatic and metastatic samples. Images are shown of both 
metastatic and non-metastatic samples, representing the range 
of staining detected (Fig. 1A).
The mRNA expression of Eplin-α was also examined 
in two EOC cell lines using RT-PCR. Eplin-α mRNA was 
expressed at relatively high levels in all cell lines (Fig. 1B).
Knock-down of Eplin-α in EOC cells. To investigate the impact 
of Eplin-α on a range of behavioural functions of ovarian 
cancer cells, Eplin-α hammerhead ribozyme transgenes were 
Figure 2. Knock-down of EPLIN-α in transfected EOC cells. RT-PCR (28 cycles) showed decreased EPLIN-α mRNA transcripts in the EPLIN-α-transfected 
cells (Rib) compared to controls (WT, pEF6) in SKOV3 and COV504 cells. GAPDH (25 cycles) was examined as an equal loading control (A). Knock-down 
of EPLIN-α protein in the same cells was verified by western blot analysis. GAPDH was used as the loading control (B). Immunofluorescence microscopy 
confirmed reduce cytoplasmic expression of EPLIN-α protein (green cytoplasmic staining) in monolayers of EPLIN-α-transfected SKOV3 and COV504 cells 
(blue, DAPI nuclear stain) (C). Bar, 100 µm.
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Figure 4. Effect of Eplin-α on adhesion of EOC cells in vitro. Effect of Eplin-α decreased expression on rapid (40 min) cell adhesion to Matrigel basement 
membrane. Knock-down of Eplin-α expression significantly increased SKOV3Eplin-αRib (A) COV504Eplin-αRib (B) cell adhesion compared to pEF6 and WT con-
trols. Data were analysed by paired t-test (Eplin-αpEF6 control). ***p<0.001. The error bars represent mean cell count/well ± SD. Images are representative fields 
of view. Data shown are the mean of three independent experiments. The SKOV3Eplin-αRib (C), COV504Eplin-αRib (D) cells with knocked down Eplin-α showed a 
markedly increased attachment using an ECIS model to measure resistance over 5 h. Data show relative change in resistance from 0 to5 h for each cell line and 
are mean of 3 independent experiments ± SD. ***p<0.001 comparing Eplin-αRib versus WT control cells.
Figure 3. Effect of EPLIN-α on in vitro growth of EOC cells. Cell numbers were measured by crystal violet absorbance after 1, 3 and 5 days growth and results 
expressed as % cell number on days 3 and 5 compared to day 1. After 5 days, growth in SKOV3Eplin-αRib, COV504Eplin-αRib cells was increased in comparison 
with the WT and pEF6 controls. Data were analysed by paired t-test. *p<0.05 **p<0.01. The error bars represent mean ± SD, data shown is the mean of three 
independent experiments.
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utilised to knock down Eplin-α. After selection using blasti-
cidin, the reduced expression of Eplin-α in the transfected cells 
was verified using RT-PCR, immunofluorescent staining and 
western blotting (Fig. 2). Decreased expression of both Eplin-α 
mRNA (~50%) (Fig. 2A) and protein (~80%) (Fig. 2B) was seen 
in SKOV3Eplin-αRib, in comparison with the controls (wild-type 
SKOV3WT and empty plasmid SKOV3pEF6). Knock-down of 
Eplin-α mRNA (~40%) and protein (~80%) was also confirmed 
in COV504Eplin-αRib cells, in comparison with the COV504WT 
and COV504pEF6 control cells. Immunofluorescent staining 
was carried out to examine the expression and localisation of 
the Eplin-α in the transfected cells (Fig. 2C). Eplin-α staining 
(green), was predominantly associated with the cytoplasm. 
Control cells, both wild-type and empty vector transfectants, 
had strong staining intensity in two EOC cell lines, with the 
majority of the cells showing more intense and frequently 
observed staining. However, in the transfected knocked down 
cells Eplin-α had minimal staining levels.
Regulation of Eplin-α expression affects the rate of cell growth 
of EOC cells. The growth capacity of the EOC cells following 
Eplin-α knock-down was examined and compared to the wild-
type and empty vector control cells using an in vitro cell growth 
assay (Fig. 3). In all transfected cells, knock-down of Eplin-α 
protein increased growth rate by both day 3 and day 5. In 
SKOV3Eplin-αRib cells, the mean cell number at day 5 was increased 
by 36% (p<0.01) compared to pEF6 control, in COV504Eplin-αRib 
cells, growth rate increased by 46% (p<0.05) (Fig. 3).
Effect of knocked down Eplin-α on cell-matrix adhesion in 
EOC cells. The effect of Eplin-α on the ability of EOC cells 
to adhere to Matrigel matrix was examined (Fig. 4A and B). 
Knock-down of Eplin-α protein caused a significant (p<0.001) 
increase of ~40% on cell-matrix adhesion in the SKOV3 
cells compared to both WT and pEF6 controls (Fig. 4A). 
Compared with COV504WT and COV504pEF6, the number 
of COV504Eplin-αRib cells that adhered was also significantly 
increased (p<0.001) by ~40% (Fig. 4B). The ECIS system 
was also used to confirm the accelerative effect of reduced 
expression of Eplin-α on SKOV3, COV504 cell adhesion. 
This was measured by change in resistance formed over the 
growth surface as cells attached from 0 to 5 h (Fig. 4C and D). 
Compared with the appropriate WT and pEF6 controls, the 
resistance was significantly increased in SKOV3Eplin-αRib and 
COV504Eplin-αRib cells, confirming that low expression of 
Eplin-α in ovarian cells increased the adhesive capability.
Effect of knocked down Eplin-α on the invasion of EOC cells. 
The potential biological relevance of reduced Eplin-α expres-
sion was further investigated using in vitro invasion assays 
over the artificial basement membrane, Matrigel. Reduced 
expression of Eplin-α in all of these cell lines caused a 50% 
increase (p<0.001) in basal invasion compared to both WT and 
pEF6 controls (Fig. 5).
Effect of Eplin-α on wounding/migration of EOC cells. A 
cellular wounding assay (Fig. 6A and B) was used to compare 
the ability of wild-type and knock-down Eplin-α cells to 
migrate. Reduced expression of Eplin-α in the two EOC cell 
lines caused a marked (≤30%) increase in migration capability 
compared to the WT control (p<0.05). The reduced ability of 
Eplin-α expression to increase ovarian cell motility was also 
confirmed by measuring the ability of cell lines to recover from 
an electrical wound generated using the ECIS system (Fig. 6C 
and D). Measurements taken 10 h post-wound also showed that 
the migration capacity of SKOV3Eplin-αRib and COV504Eplin-αRib 
were markedly increased (p<0.001) in comparison with 
wild-type control cells.
Figure 5. Effect of Eplin-α decreased-expression on the invasion of EOC cells. Cell invasion through Matrigel coated barrier was quantitated after fixing and 
staining invaded cells. Invasion capability was increased in SKOV3Eplin-αRib (A) and COV504Eplin-αRib (B) cells. Four fields of view/insert were photographed 
and counted. Images shown are from a typical field of view (x4 magnification). Data shown are the mean ± SD cell number/membrane from 3 independent 
experiments. t-test compared Eplin-αRib versus the controls for each cell line. ***p<0.001.
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Figure 6. Effect of Eplin-α expression on migration of EOC cells. Confluent monolayers of EOC cells were scratched and the distance moved by cells to cover 
the wound was measured after 12, 24 and 36 h and compared to time 0. After 36 h, SKOV3 (A) and COV504 (B) cells with knockdown of Eplin-α protein 
expression all showed significantly increased migration compared to WT or pEF6 controls (t-test *p<0.05 or **p<0.01). Images shown are taken at 0 and 36 h are 
from representative experiment. The data shown are from 3 independent experiments. ECIS confirmed the increased migratory capability of SKOV3Eplin-αRib (C) 
and COV504Eplin-αRib (D) cells compared to the appropriate empty vector control cells. At time 0 the confluent monolayer of cells was electrically wounded and 
the impedance changes were recorded over 10 h as an indication of how rapidly the cells migrated to cover the wound. Data show relative change in resistance 
from 0 to 10 h for each cell line and are the mean of 3 independent experiments ± SD. ***p<0.001 comparing Eplin-αRib versus control cells. 
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Discussion
Uncontrolled tumour cell proliferation and robust neovascular-
ization are prominent features of aggressive ovarian cancers, 
distant metastasis being a key factor in the poor prognosis 
associated with this cancer. Although great efforts in anti-
ovarian cancer therapy have been made in the past decades, 
the 5-year survival rates for ovarian cancer patients are still 
poor, and effective drugs to cure ovarian cancer patients are 
absent. To improve the prognosis, assessment and treatment of 
EOC patients, it is crucial that we identify the key molecular 
regulators of tumourigenesis and understand the key molecular 
pathways involved. However, many of these tumourigenesis 
mechanisms remain largely unknown.
Eplin-α (epithelial protein lost in neoplasm) has previously 
been found to localise with actin stress fibres and plays an 
important role in regulating actin dynamics and linking the 
catenin-cadherin complex to F-actin (2-4), suggesting a key 
role for this molecule in regulating cellular motility. It has 
been previously reported that Eplin-α has been found to be 
downregulated in a number of oral, breast, esophageal and 
prostate (5,7,8,20) cancer cell lines compared to their normal 
counterparts. Previous studies from our laboratories have 
provided data supporting a tumour/metastasis suppressive 
role for EPLIN-α, where enhanced levels of EPLIN-α can 
negatively impact on key metastatic and angiogenic traits 
in vitro and in vivo (7,8,21). Our study aimed to determine 
whether there was a relationship between Eplin-α protein 
expression and the aggressiveness of clinical ovarian cancer. 
Immunohistochemical analysis demonstrated that only a small 
number of ovarian cancer tissues expressed Eplin-α protein, 
but conclusions were limited by the relatively small sample 
size used. The majority of tumours, both metastatic and 
non-metastatic, were negative for Eplin-α (80%), and in the 
tissues where positive staining was seen there appeared to be 
no distinct difference in the localisation and intensity of stain. 
Due to the relatively small number of clinical samples included 
in our study, the results did not enable statistical analysis. In 
some tumour types, including breast and esophageal cancer, 
EPLIN-α may be considered a suitable biomarker for tumour 
progression, with high EPLIN-α being associated with favour-
able prognosis and reduced EPLIN-α a poorer outcome (7,20). 
EPLIN-α expression is variable between individuals which 
may reflect a range of differences in ovarian cancer aetiology 
or disease stages when samples were taken. Conclusive results 
can only be obtained if a larger cohort is studied.
A relatively small number of in vitro studies have reported 
in which the function of EPLIN-α is characterized. These 
studies with a panel of human cell lines have shown EPLIN-α 
is differentially expressed with an inverse correlation between 
cell differentiation, invasive capability and EPLIN-α expression 
(5,7,8,20), for example, MDA-MB-231 cells, considered highly 
invasive, were negative for Eplin-α expression (7). Our present 
investigation showed that the ovarian tumour cell lines, SKOV3 
and COV504, which both demonstrated reasonable (but not 
high) invasive capability, also expressed a relatively high level of 
EPLIN-α mRNA and protein suggesting other factors in addi-
tion to EPLIN-α expression may also be involved in regulating 
invasion. However, cellular function tests did demonstrate that 
the presence of EPLIN-α was related to the inhibition of the 
ovarian cancer cell aggressiveness. Knock-down of EPLIN-α 
expression resulted in an increase in the in vitro growth rate of 
SKOV3 and COV504 cells during the 3 and 5-day incubation 
periods (p<0.01, p<0.05). Knock-down of EPLIN-α expression 
also impacted cell-matrix adhesion significantly decreasing it 
compared to that of pEF6 control cells.
We have demonstrated here that knock-down of EPLIN-α 
expression resulted in a strong increase in ovarian cancer cell 
line growth, adhesion, invasion and migration, in comparison 
with control cells. The inhibitory effect of EPLIN-α on 
ovarian cancer cell growth is in agreement with the find-
ings in breast, prostate, esophageal and endothelial cell lines 
(7,8,20,21). Although the precise molecular mechanisms by 
which EPLIN-α inhibits tumour growth remains unknown, 
research studies provide conclusive evidence that reduction of 
EPLIN has the potential to disrupt cell-cell adhesion via disor-
ganization of the adherens junctions, which promotes IGF1R 
signalling. This is followed by the attenuation of E-cadherin 
expression and an EMT-like phenotype (12). Further studies 
are required to reveal the exact molecular mechanisms and 
signalling pathways through which EPLIN-α modulates 
cancer cell migration and invasion.
Our studies suggest that decreased expression of EPLIN-α 
is seen in cancerous tissue where it may be associated with a 
poorer prognosis making EPLIN-α loss a potential prognostic 
marker. As far as the authors are aware, this is the first study 
examining the expression of EPLIN-α in human EOC tissue 
and reporting the effect of reduced EPLIN-α expression on 
EOC cell line behaviour.
In conclusion, this study shows that the knock-down of 
EPLIN-α protein can increase the aggressiveness of human 
ovarian cancer, furthermore, it suggests that preventing 
EPLIN-α degradation, or partially restoring EPLIN-α expres-
sion, could be a possible novel strategy to treat aggressive 
ovarian cancer growth and metastasis. These data clearly indi-
cate that EPLIN-α may potentially have use as a prognostic 
indicator and that the molecule may act as a protective factor 
in patients with EOC.
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